Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-676,608
Closed -$2.12M 212
2024
Q4
$2.12M Sell
676,608
-466
-0.1% -$2.26K 0.29% 78
2024
Q3
$3.34M Sell
677,074
-798,000
-54% -$4.12M 0.47% 60
2024
Q2
$6.51M Sell
1,475,074
-89,266
-6% -$418K 1.13% 27
2024
Q1
$10.6M Sell
1,564,340
-426,665
-21% -$3.24M 1.16% 25
2023
Q4
$14.9M Sell
1,991,005
-927,421
-32% -$7.92M 1.39% 23
2023
Q3
$29.7M Hold
2,918,426
3.57% 5
2023
Q2
$61M Buy
+2,918,426
New +$59.7M 9.71% 1

Other funds holding SLRN

Ikarian Capital's SLRN Position: Q1 2025 in Review

Ikarian Capital sold out of ACELYRIN (SLRN) in Q1 2025, closing a stake of 676,608 shares — an estimated $2.12M sold.

Ikarian Capital first reported a position in SLRN in Q2 2023 and held it in 7 quarters. The position peaked at $61M in Q2 2023. 105 funds tracked by Wall St. Rank hold SLRN as of Q1 2025.

  • Ikarian Capital reported no remaining ACELYRIN position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 676,608 ACELYRIN shares in Q1 2025, an estimated $2.12M.
  • Ikarian Capital first reported a position in ACELYRIN in Q2 2023 and held it in 7 quarters.
  • Ikarian Capital's ACELYRIN position peaked at $61M in Q2 2023.
  • 105 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.